Update shared on04 Sep 2025
With both the Future P/E (41.57x) and Net Profit Margin (22.70%) remaining essentially unchanged, analysts have left their consensus price target for Sun Pharmaceutical Industries steady at ₹1930.
What's in the News
- Sun Pharma announced positive top-line results from two Phase 3 studies (INSPIRE-1 & INSPIRE-2) of ILUMYA (tildrakizumab) for active psoriatic arthritis, meeting primary endpoints with no new safety signals.
- The company launched LEQSELVI (deuruxolitinib) 8 mg tablets in the U.S. for adults with severe alopecia areata, offering rapid hair regrowth and addressing significant unmet needs.
- Subsidiary Sun Pharma (Hainan) Company Limited was incorporated in China.
- The Board will meet to consider and approve unaudited financial results for the quarter ended 30 June 2025.
- US FDA issued a Form-483 with 8 observations after a GMP inspection at the Halol facility in Gujarat.
- Kirti Ganorkar was appointed managing director, succeeding Dilip Shanghvi (who becomes executive chairman and will focus on specialty portfolio and strategy development), pending shareholder approval.
Valuation Changes
Summary of Valuation Changes for Sun Pharmaceutical Industries
- The Consensus Analyst Price Target remained effectively unchanged, at ₹1930.
- The Future P/E for Sun Pharmaceutical Industries remained effectively unchanged, moving only marginally from 41.59x to 41.57x.
- The Net Profit Margin for Sun Pharmaceutical Industries remained effectively unchanged, at 22.70%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.